Mesenchymal stem cells for the treatment of spinocerebellar ataxia

doi:10.3969/j.issn.2095-4344.2013.27.012

Abstract

Abstract:

BACKGROUND: Spinocerebellar ataxia is a common neurodegenerative disease characterized by slowly progressive movement incoordination of the limbs. It responds badly to common medication.
OBJECTIVE: To observe the clinical effect of autologous bone marrow mesenchymal stem cells and allogeneic umbilical cord mesenchymal stem cells tranfusion in the treatment of spinocerebellar ataxia.
METHODS: A total of 27 spinocerebellar ataxia patients treated with mesenchymal stem cells treatment were included for comprehensive statistical analysis. Among these patients, six patients received autologous bone marrow mesenchymal stem cells lumbar puncture treatment and 21 patients received allogeneic umbilical cord mesenchymal stem cells lumbar puncture treatment combined with intravenous infusion. The neurologic function of the patients in the two groups was evaluated with International Cooperative Ataxia Rating Scale before and after treatment.
RESULTS AND CONCLUSION: There was no obvious adverse effect in the 27 spinocerebellar ataxia patients during, before or after mesenchymal stem cells treatment. The effect of autologous bone marrow mesenchymal stem cells in six patents was not significant; for the other 21 patients treated with allogeneic umbilical cord mesenchymal stem cells transfusion, the subjective symptoms of the patients were improved, and the International Cooperative Ataxia Rating Scale scores were decreased significantly at 3 months after treatment when compared with those before treatment (P < 0.05). The results suggest that umbilical cord mesenchymal stem cells treatment is safe and able to ameliorate the clinical symptoms and improve life quality of spinocerebellar ataxia patients to some extent.

Key words: stem cells, stem cell transplantation, umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells, spinocerebellar ataxia, dyskinesia, lumbar puncture, International Cooperative Ataxia Rating Scale, allogeneic umbilical cord, cell transplantation, cord blood, immune phenotype, dementia, Natural Science Foundation of China, stem cell photographs-containing paper

CLC Number:

R394.2

Hu Jing-qiong, Ouyang Wei-xiang, Li Hui-yu, Wang Jun-feng, Lu Cong, Zhang Lan-nan, Xu Hai-bo, Chen Li-li, Huang Shi-ang. Mesenchymal stem cells for the treatment of spinocerebellar ataxia[J]. Chinese Journal of Tissue Engineering Research, doi: 10.3969/j.issn.2095-4344.2013.27.012.

Figures/Tables 5

References

[1] Koch P, Breuer P, Peitz M, et al.Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature. 2011;480(7378):543-546.

[2] Paulson H.Machado-Joseph Disease: from first descriptions to new perspectives. Handb Clin Neurol. 2012;103:437-449.

[3] D'Abreu A, França MC Jr, Paulson HL, et al. New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease). Curr Opin Neurol. 2008;21(2): 111-116.

[4] Yamada M, Sato T, Tsuji S, Takahashi H. CAG repeat disorder models and human neuropathology: similarities and differences. Acta Neuropathol. 2008;115(1):71-86.

[5] Zhang L, Tan X, Dong C, et al.In vitro differentiation of human umbilical cord mesenchymal stem cells (hUCMSCs), derived from Wharton's jelly, into choline acetyltransferase (ChAT)-positive cells. Int J Dev Neurosci. 2012;30(6): 471-477.

[6] Datta I, Mishra S, Mohanty L, et al.Neuronal plasticity of human Wharton's jelly mesenchymal stromal cells to the dopaminergic cell type compared with human bone marrow mesenchymal stromal cells.Cytotherapy. 2011;13(8):918-932.

[7] Zhang HT, Fan J, Cai YQ, et al. Human Wharton's jelly cells can be induced to differentiate into growth factor-secreting oligodendrocyte progenitor-like cells.Differentiation. 2010; 79(1):15-20.

[8] Peng J, Wang Y, Zhang L, et al. Human umbilical cord Wharton's jelly-derived mesenchymal stem cells differentiate into a Schwann-cell phenotype and promote neurite outgrowth in vitro. Brain Res Bull. 2011;84(3):235-243.

[9] Ding DC, Shyu WC, Lin S Z. Mesenchymal stem cells. Cell Transplant. 2011;20(1):5-14.

[10] Caimi PF, Reese J, Lee Z, et al. Emerging therapeutic approaches for multipotent mesenchymal stromal cells. Curr Opin Hematol. 2010;17(6):505-513.

[11] Lin YC, Ko TL, Shih YH,et al.Human umbilical mesenchymal stem cells promote recovery after ischemic stroke. Stroke. 2011;42(7):2045-2053.

[12] Lim JY, Jeong CH, Jun JA,et al.Therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells after intrathecal administration by lumbar puncture in a rat model of cerebral ischemia.Stem Cell Res Ther. 2011;22:2(5):38.

[13] Kim ES, Ahn SY, Im GH, et al.Human umbilical cord blood-derived mesenchymal stem cell transplantation attenuates severe brain injury by permanent middle cerebral artery occlusion in newborn rats.Pediatr Res. 2012;72(3):277- 284.

[14] Schira J, Gasis M, Estrada V, et al.Significant clinical, neuropathological and behavioural recovery from acute spinal cord trauma by transplantation of a well-defined somatic stem cell from human umbilical cord blood. Brain. 2012;135(Pt 2): 431-446.

[15] Hu SL, Luo HS, Li JT, et al. Functional recovery in acute traumatic spinal cord injury after transplantation of human umbilical cord mesenchymal stem cells. Crit Care Med. 2010;38(11):2181-2189.

[16] Matsuse D, Kitada M, Kohama M,et al. Human umbilical cord-derived mesenchymal stromal cells differentiate into functional Schwann cells that sustain peripheral nerve regeneration.J Neuropathol Exp Neurol. 2010;69(9):973-985.

[17] Pang KM, Sung MA, Alrash-dan MS, et al. Trans-plantation of mesenchymal stem cells from human umbilical cord versus human umbilical cord blood for peripheral nerve regenera-tion. Neural Regen Res. 2010;5(11):838-845.

[18] Seo Y, Yang SR, Jee MK, et al.Human umbilical cord blood-derived mesenchymal stem cells protect against neuronal cell death and ameliorate motor deficits in Niemann Pick type C1 mice. Cell Transplant. 2011;20(7):1033-1047.

[19] Chang YK, Chen MH, Chiang YH, et al.Mesenchymal stem cell transplantation ameliorates motor function deterioration of spinocerebellar ataxia by rescuing cerebellar Purkinje cells.J Biomed Sci. 2011 Aug 8;18:54.

[20] Jones J, Jaramillo-Merchán J, Bueno C, et al. Mesenchymal stem cells rescue Purkinje cells and improve motor functions in a mouse model of cerebellar ataxia. Neurobiol Dis. 2010; 40(2):415-423.

[21] Jones J, Jaramillo-Merchán J, Bueno C, et al. Mesenchymal stem cells rescue Purkinje cells and improve motor functions in a mouse model of cerebellar ataxia Neurobiol Dis. 2010; 40(2):415-423.

[22] Dey R, Kemp K, Gray E, et al.Human Mesenchymal Stem Cells Increase Anti-oxidant Defences in Cells Derived from Patients with Friedreich's Ataxia. Cerebellum. 2012 Jul 24.

[23] Kemp K, Mallam E, Hares K, et al.Mesenchymal stem cells restore frataxin expression and increase hydrogen peroxide scavenging enzymes in Friedreich ataxia fibroblasts. PLoS One. 2011;6(10):e26098.

[24] Yang XF, Xu YF, Lü NW, et al. Umbilical cord mesenchymal stem cell transplantation for the treatment of Duchenne muscular dystrophy. Neural Regen Res. 2011;6(10): 785-789.

[25] Dongmei H, Jing L, Mei X, et al. Clinical analysis of the treatment of spinocerebellar ataxia and multiple system atrophy-cerebellar type with umbilical cord mesenchymal stromal cells. Cytotherapy. 2011;13(8):913-917.

[26] Trouillas P,Takayanagi T,Hallett M,et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J NeurolSci 1997;145:205–211.

[27] Matos CA, de Macedo-Ribeiro S, Carvalho AL. C Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease. Prog Neurobiol. 2011;95(1):26-48.

[28] Dalous J, Larghero J, Baud O.Transplantation of umbilical cord-derived mesenchymal stem cells as a novel strategy to protect the central nervous system: technical aspects, preclinical studies, and clinical perspectives.Pediatr Res. 2012;71(4 Pt 2):482-490.

[29] Taghizadeh RR, Cetrulo KJ, Cetrulo CL.Wharton's Jelly stem cells: future clinical applications.Placenta. 2011;32 Suppl 4: S311-315.

[30] Fan CG, Zhang QJ, Zhou JR.Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord.Stem Cell Rev. 2011;7(1):195-207.

[31] Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol. 2012;67(1):1-8.

[32] Momin EN, Mohyeldin A, Zaidi HA, et al. Mesenchymal stem cells: new approaches for the treatment of neurological diseases. Curr Stem Cell Res Ther. 2010;5(4):326-344.

[33] Zhang MJ, Sun JJ, Qian L, et al.Human umbilical mesenchymal stem cells enhance the expression of neurotrophic factors and protect ataxic mice. Brain Res. 2011; 1402:122-131.